Compare · ALMR vs RVTY
ALMR vs RVTY
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $11.28B, about 7.8x ALMR ($1.45B).
- Over the past year, ALMR is down 5.7% and RVTY is up 9.5% - RVTY leads by 15.1 points.
- RVTY has been more active in the news (12 items in the past 4 weeks vs 6 for ALMR).
- RVTY has more recent analyst coverage (19 ratings vs 5 for ALMR).
PerformanceALMR-5.65%RVTY+7.64%
2026-04-17+0.00%2026-06-03
- Company
- Alamar Biosciences Inc.
- Revvity Inc.
- Price
- $20.94+0.53%
- $101.15+0.77%
- Market cap
- $1.45B
- $11.28B
- 1M return
- -12.20%
- +16.81%
- 1Y return
- -5.65%
- +9.46%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 6
- 12
- Recent ratings
- 5
- 19
Latest ALMR
- Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
- Analyst initiated coverage on Alamar Biosciences with a new price target
- BofA Securities initiated coverage on Alamar Biosciences with a new price target
- TD Cowen initiated coverage on Alamar Biosciences with a new price target
- Leerink Partners initiated coverage on Alamar Biosciences with a new price target
- Stifel initiated coverage on Alamar Biosciences with a new price target
- SEC Form 10-Q filed by Alamar Biosciences Inc.
- Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alamar Biosciences Reports First Quarter 2026 Financial Results
- Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)